VSIG10 (V-set and immunoglobulin domain-containing 10) is an intricate component of the immunoglobulin superfamily, primarily implicated in cellular adhesion and signaling pathways that are crucial for maintaining cellular integrity and homeostasis. The protein's structural features, including V-set and immunoglobulin domains, play pivotal roles in facilitating cell-cell interactions and intracellular communication. These interactions are essential for a multitude of cellular processes, including proliferation, differentiation, and migration, positioning VSIG10 as a key mediator in the orchestration of cellular behavior and tissue organization. Its function, deeply rooted in the regulation of cell adhesion mechanisms, underscores the protein's importance in cellular cohesion and the establishment of functional cellular assemblies. This regulatory capacity of VSIG10 is contingent upon its ability to interact with other cellular components, delineating a complex network of interactions that modulate cellular responses to various physiological stimuli.
The inhibition of VSIG10 involves mechanisms that disrupt its normal function in cell adhesion and signaling pathways. Such inhibition can be achieved through the interference of its protein-protein interactions, which are fundamental for the activation of downstream signaling cascades. The disruption of these interactions could manifest through the competitive binding of inhibitors to the domains of VSIG10 that are crucial for its interaction with other cell surface proteins, thereby impeding its ability to mediate cell-cell adhesion and signaling. Additionally, post-translational modifications of VSIG10, such as phosphorylation or ubiquitination, could also modulate its activity by altering its conformation or stability, thus affecting its functional capacity. The precise regulation of VSIG10 through inhibition is essential for modulating cellular processes, highlighting the importance of understanding these inhibitory mechanisms. Such knowledge contributes to a deeper comprehension of the regulatory networks governing cellular behavior, offering insights into the intricate balance of signaling pathways that sustain cellular and tissue homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that inhibits VEGFR-2, RAF kinases, and other kinases involved in tumor angiogenesis and proliferation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases, including VEGFR-2, disrupting angiogenesis and tumor growth by inhibiting signaling pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a selective VEGFR inhibitor that prevents angiogenesis by blocking the tyrosine kinase activity of VEGFR-2 and other related kinases. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that suppresses angiogenesis by inhibiting VEGFR-2 and other kinases associated with tumor growth and vascularization. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Lenvatinib inhibits VEGFR-2 and other kinases, leading to reduced angiogenesis and tumor growth by blocking the VEGF signaling pathway. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
XL-184 (Cabozantinib) is a tyrosine kinase inhibitor that targets VEGFR-2, disrupting angiogenesis and inhibiting the growth of blood vessels in tumors. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR-2 and other kinases, reducing angiogenesis and tumor progression by disrupting the VEGF signaling pathway. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Nintedanib is a multi-kinase inhibitor that targets VEGFR-2 and other kinases, inhibiting angiogenesis and fibrosis in diseases like idiopathic pulmonary fibrosis. | ||||||
Cediranib | 288383-20-0 | sc-483599 sc-483599A sc-483599B | 5 mg 10 mg 25 mg | $137.00 $220.00 $406.00 | ||
Cediranib is a VEGFR-2 inhibitor that hinders angiogenesis by blocking the receptor's tyrosine kinase activity, blocking VEGF-mediated signaling. | ||||||
Tivozanib | 475108-18-0 | sc-475339 | 5 mg | $320.00 | ||
VEGFR Tyrosine Kinase Inhibitor IV selectively targets VEGFR-1, -2, and -3, inhibiting angiogenesis by disrupting VEGF signaling and suppressing blood vessel growth in tumors. | ||||||